Dave Mack fell in love with radio at an early age, and after 30 years the affair continues. His radio career has taken him to some great cities but his home has been in Alabama since 1994. Dave was introduced to Alabama in a unique way while attending church at Goshen United Methodist Church on Palm Sunday 1994 when a tornado hit the church killing more than 20 and injuring many more, including Dave. Having an up close and personal experience with Severe weather, Dave has provided long form severe weather coverage on several stations and is involved with public speaking about severe weather preparedness. Dave Mack has lived a unique life that includes stand up comedy as well as hosting his own regional television show, and most recently added "Feature Film Actor" to his resume having co-starred in the feature film "Prodigal". Dave is scheduled to star in two additional feature films in 2012. Dave and his wife LaDonna (a lifelong Alabama resident) have 4 children and multiple pets including Dave's special friend....his chihuahua "Tanner".
(Reuters) - A presidential ethics panel has opened the door to testing an anthrax vaccine on children as young as infants, bringing an angry response from critics who say the children would be guinea pigs in a study that would never help them and might harm them.
The report, however, released on Tuesday by the Presidential Commission for the Study of Bioethical Issues, said researchers would have to overcome numerous hurdles before launching an anthrax-vaccine trial in children. It now goes to Secretary of Health and Human Services Kathleen Sebelius, who will decide whether to take the steps the commission recommended.
The one anthrax vaccine approved in the United States, called BioThrax, is made by Emergent BioSolutions Inc of Rockville, Maryland. The company reported $215.9 million in sales of BioThrax, its only licensed product, in 2012.
The ethics commission took up the issue after a biodefense panel recommended in 2011 that the anthrax vaccine be tested in children. That endorsement, by the National Biodefense Science Board, came with the caveat that such a study also get the go-ahead from a bioethics panel.
It did, albeit conditionally.